Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases.

[1]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A Iliadis,et al.  Population pharmacokinetics of mitoxantrone performed by a NONMEM method. , 1989, Journal of pharmaceutical sciences.

[3]  N. Mulder,et al.  A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Ratain,et al.  Pharmacokinetics and pharmacodynamics of long‐term continuous‐infusion doxorubicin , 1989, Clinical pharmacology and therapeutics.

[5]  J. Robert,et al.  Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients. , 1989, European journal of cancer & clinical oncology.

[6]  F. Demard,et al.  5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. , 1989, British Journal of Cancer.

[7]  M. Moore,et al.  Therapeutic Drug Monitoring in Oncology , 1987, Clinical pharmacokinetics.

[8]  R. Schilsky,et al.  Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. , 1987, Cancer research.

[9]  M. Egorin,et al.  Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. , 1987, Cancer research.

[10]  S. McGrath,et al.  High-performance liquid chromatographic assay for mitoxantrone in plasma using electrochemical detection. , 1987, Journal of chromatography.

[11]  D. V. Von Hoff,et al.  Mitoxantrone: a new anticancer drug with significant clinical activity. , 1986, Annals of internal medicine.

[12]  E. D. Grady,et al.  Continuous infusion chemotherapy. , 1986, Journal of the Medical Association of Georgia.

[13]  D. Alberts,et al.  Disposition of mitoxantrone in cancer patients. , 1985, Cancer research.

[14]  N. Vogelzang.  Continuous infusion chemotherapy: a critical review. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Wallace,et al.  Molecular and biochemical pharmacology of mitoxantrone. , 1983, Cancer treatment reviews.

[16]  D. Alberts,et al.  Disposition of mitoxantrone in patients. , 1983, Cancer treatment reviews.

[17]  F. Schabel,et al.  Therapeutic activity of mitoxantrone and ametantrone against murine tumors. , 1983, Cancer treatment reviews.

[18]  B. Barlogie,et al.  Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro. , 1983, Cancer research.

[19]  E. Modest,et al.  Phase I trial of mitoxantrone by 24-hour continuous infusion. , 1983, Cancer treatment reports.

[20]  J. Stewart,et al.  Clinical and clinical pharmacologic studies of mitoxantrone. , 1982, Cancer treatment reports.

[21]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[22]  C. Coltman,et al.  Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. , 1980, Cancer research.